Tech Company Financing Transactions
QuVa Pharma Funding Round
QuVa Pharma, based in Sugar Land, scored $275 million from Goldman Sachs and Owl Rock.
Transaction Overview
Company Name
Announced On
5/7/2021
Transaction Type
Debt
Amount
$275,000,000
Round
Undisclosed
Investors
Goldman Sachs (Lead Investor)
Proceeds Purpose
The financing enables QuVa Pharma to meet the needs of its approximately 2,000 hospital customers, add more hospitals to the platform, and expand its 200 SKU product portfolio.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3 Sugar Creek Center Blvd. 250
Sugar Land, TX 77478
USA
Sugar Land, TX 77478
USA
Phone
Website
Email Address
Overview
QuVa Pharma will be the industry's leading 503B platform and the partner of choice for compliance-oriented healthcare facilities looking to ensure quality, safe and consistent supply of medications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stuart Hinchen
Chief Financial Officer
Brett Coverdale
Chief Operating Officer
Scott Aladeen
Vice President
Varsha Gaitonde
Vice President
Donna Kohut
Vice President
Travis Leeah
VP - Bus. Development
Peter Jenkins
VP - Human Resources
Tracey Gibbs
VP - Marketing
Michael Scouvart
VP - Operations
Michael Rutkowski
VP - Regulatory Affairs
David Short
VP - Sales
Ray Dixon
Browse more venture capital transactions:
Prev: 5/7/2021: Upshot Technologies venture capital transaction
Next: 5/7/2021: Swimply venture capital transaction
Share this article
News on VC Transactions
We report on every notable VC transaction. All VC database entries reported here come from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs